1. Cholinesterase inhibitors

3. •Cholinesterase is enzyme that cleaves acetylcholine to acetate and choline to end its action , It’s located in both pre and postsynapse.

4. •Cholinesterase inhibitors inactivate acetylcholinesterase by reversibly binding to the enzyme so , it is indirectly provide a cholinergic action by prolonging the life time of acetylcholine

6. So , cholinesterase inhibitors are cholinomimic .

7. Effect of cholenomimic on different organ systems: (parasympathetic stimulation)

8. Cardiovascular receptors— The predominant muscarinic effect on the heart is
bradycardia that can progress to sinus arrest.

9. Pulmonary receptors— Muscarinic stimulation can result in bronchospasm
(smooth muscle contraction) and increased respiratory tract secretions.

10. Gastrointestinal receptors— Muscarinic stimulation increases peristaltic
activity (esophageal, gastric, and intestinal) and glandular secretions (eg,
salivary). Postoperative nausea, vomiting, and fecal incontinence have been
attributed to the use of cholinesterase inhibitors

11. Eye_ Miosis (constrict the pupil) .

13. NEOSTIGMINE

14. Neostigmine consists of a carbamate moiety and a quaternary ammonium group . The carbamate moiety provides covalent bonding to acetylcholinesterase. The quaternary ammonium group renders the molecule lipid insoluble, so that it cannot pass through the blood–brain barrier.

15. •Polar/lipid insoluble: doesn’t enter the CNS
•Polar/lipid insoluble: doesn’t enter the CNS . •Dosage & Packaging : The maximum recommended dose of neostigmine is 0.08 mg/kg (up to 5 mg in adults), but smaller amounts often suffice and larger doses have also been given safely. •Some clinicians use a dose of 0.04 mg/kg (or 2.5 mg) if the preexisting blockade is mild to moderate and a dose of 0.08 mg/kg (or 5 mg) if intense paralysis is being reversed; other clinicians use the “full dose” for all patients.

16. •The effects of neostigmine (0
•The effects of neostigmine (0.04 mg/kg) are usually apparent in 5 min, peak at 10 min, and last more than 1 h.

17. The duration of action is prolonged in geriatric patients.

18. Clinical uses
•Primary action? at the end of operation available to compete with the nondepolarizing agent, thereby reestablishing normal neuromuscular transmission
Note: any prolongation of action of a nondepolarizing muscle relaxant from renal or hepatic insufficiency will probably be accompanied by a corresponding increase in the duration of action of a cholinesterase inhibitor.
•It can be used for urinary retention resulting from general anesthesia
•In the treatment of myasthenia gravis

19. Neostigmine increase amount of Ach which competes with non depolarizing drugs and decrease their effect but leads to many side effects resulting from increased Ach concentration and activation of parasympathetic system leading to : bradycardia ,meiosis, hyper-salivation,intestinal hypermotility ; so we combine atropine(or Glycopyrrolate) with neostigmine in one syringe to counteract the side effects (0.4 mg of atropine per 1 mg of neostigmine)..

20. Repeat again :
Postoperative nausea, vomiting, and fecal incontinence have been attributed to the use of cholinesterase inhibitors . It has been reported that neostigmine crosses the placenta, resulting in fetal bradycardia . Neostigmine is also used to treat myasthenia gravis, urinary bladder atony, and paralytic ileus.

21. Other :
•Pyridostigmine ; slower onset and less potent •Edrophonium : less potent but the most rapid onset of action and shortest duration . •Physostigmine ; lipid soluble so can cross BBB(the only one)

23. The onset of action of pyridostigmine is slower (10–15 min) than that of neostigmine, and its duration is slightly longer (>2 h).

25. Edrophonium has the most rapid onset of action (1–2 min) and the shortest duration of effect of any of the cholinesterase inhibitors.

27. The lipid solubility and central nervous system penetration of physostigmine limit its usefulness as a reversal agent for nondepolarizing blockade, but make it effective in the treatment of central anticholinergic actions of scopolamine or overdoses of atropine. It reportedly partially antagonizes morphine induced respiratory depression, presumably because morphine reduces acetylcholine release in the brain. In contrast to other cholinesterase inhibitors, physostigmine is almost completely metabolized by plasma esterases, so renal excretion is not important.

28. Thank you